Status:
WITHDRAWN
Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
Lead Sponsor:
Children's Hospital of Philadelphia
Conditions:
Diabetes
Eligibility:
All Genders
12-20 years
Phase:
NA
Brief Summary
This study will test the hypothesis that oral repaglinide is equivalent to insulin in the treatment of new-onset CFRD in adolescents. In addition, successful treatment of CFRD with repaglinide will im...
Detailed Description
This study will test the hypothesis that oral repaglinide is equivalent to insulin in the treatment of new-onset CFRD. This hypothesis will be tested using the following aims: Specific Aim 1: To dete...
Eligibility Criteria
Inclusion
- Cystic Fibrosis, Blood glucose concerning for diabetes -
Exclusion
- Known Cystic Fibrosis-Related Diabetes, Liver Disease, FEV1\<40%
- \-
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00231192
Start Date
October 1 2005
End Date
August 1 2007
Last Update
March 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104-4399